principle was first applied successfully with antineoplastic drugs (Astier et al., 1988 , Chiannikulchaï et al., 1989 . To date, drug carriers have proved to be of potential interest in the treatment of intracellular macrophage infections (Fattal et al., 1989) , including visceral leishmaniases.
To improve the condition of patients with a chronic or relapsing course following drug therapy, more efficient and easily administrable drugs are required (Croft et al., 1991) . Treatment with pentamidine is not fully effective and has toxic side effects, nevertheless it is used against species such as Leishmania braziliensis (Soto et al., 1994) or after failure of treatment with other drugs (Croft & Davidson, 1993 et al., 1993) . In vivo, with a leishmaniasis/BALB/c mouse model, these results were confirmed by light microscopy (Fusai et al, 1994) .
The aims of the present study were to localize the nanoparticles in the liver by transmission electron microscopy (TEM), to confirm that they are harmless to the host cells, to examine the parasite changes in the Kupffer cells of mice treated with bound pentamidine and to compare the changes in groups which were untreated or treated with free pentamidine.
MATERIALS AND METHODS

S
lowly biodegradable polymethacrylic nanoparticles, with diameter of up to about 300 nm were used as drug carriers. The number of nanoparticles per ml was estimated in function of polymeric density and of the volume of one nanoparticle. They were loaded with pentamidine by ionic binding on free carboxylic groups, as previously described (Paul et al., 1997) .
Pentamidine bound nanoparticles were assayed on the murine model of visceral leishmaniasis as previously described (Fusai et al., 1993) . Briefly, promastigotes of L. major MON 74, cryopreserved or maintained in golden hamsters were cultivated for this study on RPMI medium. On day 0, 4 x 10 7 infective promastigotes were injected via the tail vein. The mice were then randomly divided into six groups of ten animals (Table I) Group 1: Untreated control mice: the parasite burden, considered as 100 %, reached 12 x 10 8 . Group 2: Glucantime treated mice: the residual burden percentage dropped dramatically. The difference between Glucantime-treated and the bound pentamidine-treated mice was small. Group 3: Bound pentamidine-treated mice: the residual parasite burden fell to 23 %. Group 4: Unloaded nanoparticle treated mice: nanoparticles were ineffective in reducing the burden. Group 5: With the usual dosage of 2.28 mg/kg x 3 free pentamidine, the burden of 48 % was the average one expected. Group 6: At the low dosage of 0.17 mg/kg x 3 free pentamidine did not reduce the burden effectively. 
RESULTS
Electron microscopy study revealed the following features:
CONTROL GROUPS
• Untreated mice
In the Kupffer cells of untreated mice (Fig. 2) , amastigotes exhibited their well known characteristic structures: a condensed kinetoplast, a mitochondrion with a double wall membrane and clearly delineated cristae.
The ribosomes, nucleus, microtubular and flagellar structures were intact. They had the morphology reported by different authors (Langreth et al., 1983 , Molyneux & Killick-Kendrick, 1987 ).
• Mice treated with free pentamidine
Free pentamidine did not alter the kinetoplast (Fig. 5) at the dose of 0.17 mg/kg, i. e. the low dosage targeted in nanoparticles. However, at the usual dose of 2.28 mg/kg, it caused the typical ultrastructural changes induced by pentamidine (Croft & Brazil, 1982 , Langreth et al., 1983 , i-e. the mitochondrion was greatly distended, the matrix contained fragments of mitochondrial membrane and the kinetoplast was disrupted and electron-dense. The ribosomes were segregated and depleted (Fig. 6 ).
MICE TREATED WITH BOUND-PENTAMIDINE
Effective phagocytosis of nanoparticles was frequently observed, as demonstrated in Figure 3 . On this section, up to 300 nanoparticles were concentrated around the nucleus of a Küpffer cell. Nanoparticles were also present in the lysosomial compartment of the parasitized cell but did not enter the parasite, although they were located close to it (Fig. 4) .
Amastigotes displayed various ultrastructural changes, especially in the kinetoplast which was more dense and seemed free in a ruptured mitochondrion.
Moreover, the mitochondrion lost its cristae and a part of its matrix. The ribosomes were segregated and depleted ( Fig. 8 and 9 ). Other views showed profiles of swollen mitochondrion, but the microtubule of the flagellum and those of subpellicular structures were unchanged (Fig. 10) . The proliferation of pseudomyelinic structures was frequently observed in these treated parasites (Fig. 11 ).
In the liver of mice treated with unloaded nanoparticles ( Fig. 7 ) and loaded nanoparticles (Fig. 8) Most publications concern other species (Croft & Brazil, 1982; Langreth et al., 1983; Hentzer & Kobayasi, 1977) .
In their review, Molyneux & Killick-Kendrick (1987) hypothesized that Leishmania, whatever the species, could have a similar configuration and ultrastructural morphology.
In this study, the percent of decrease in the parasite burden in the mice treated with bound pentamidine was established by the Stauber method, which is limited to a light microscopy examination. The ultrastructural study confirmed that, in these mice, the alte- observed multivesiculate bodies that we did not see.
The mode of action of pentamidine is not quite clear and the images we obtained did not allow us to propose other hypothesis than those already suggested by different authors (Calonge et al., 1996 , Kandpal et al., 1996 . However, there is a reason to believe that the similarity of the ultrastructural changes in the group of mice treated with free and the group treated with bound pentamidine is due to a similar mode of action.
The close contact between parasitophorous vacuole (PV) and phagolysosomes containing nanoparticles may be of crucial importance. Most of our micrographs show nanoparticles inside lysosomes, sometimes, in the PV, but we also observed free nanoparticles in the cell cytoplasm (as observed in the Figs. 8 and 9. -Leisbmania in a Küpffer cell of a mouse treated with bound pentamidine (concentration: 0,17 mg/kg). The host cell does not exhibit alteration (Fig. 8) . The parasite (P) is shown with a higher magnification in Figure 9 ; the kinetoplast and mitochondrion (M) exhibit major changes: the kinetoplast (K) is very electrondense and its membrane is disrupted, a part of the matrix is lost. In a profile of the mitochondrion, the membrane is also disrupted and if small cristae are still visible, the matrix seems being dispersed. Ribosomes are segregated and depleted. Nucleoplasma of the nucleus is clear (x 6,000, and x 19,500). Fig. 10 . -Leishmania in a Küpffer cell of a mouse treated with bound pentamidine, a swollen mitochondrion (M) and segregated ribosomes contrast with the intact appearance of flagellar structures (F) and subpellicular microtubules (arrow-head) (x 45,000). Fig. 11 . -Leishmania in a Kupffer cell of a mouse treated with bound pentamidine, besides the usual changes due to pentamidine, more numerous pseudomyelinic multilamellar structures (L) than in controls can be observed (x 22.000); insert: a higher magnification of one of these structures (x 90,000).
ULTRASTRUCTURAL CHANGES OF L. MAJOR DUE TO BOUND-PE
As far as we know, the type of carrier used here is the first to be loaded with pentamidine. Methacrylate polymer nanoparticles, which allow the ionic binding of drugs, have the advantage of releasing drugs at a low pH, as encountered in the lysosomes. The release of the drug in situ close to the target, may reduce drug toxicity to the host. The lack of immediate side effects in the mice treated with bound pentamidine was evident. Pentamidine tolerance and toxicity could be improved by the use of drug carriers. Evaluation of these nanoparticles showed that the carrier was not toxic either, in vitro, for rat liver cells or, in vivo, in rabbit (Rolland, 1988) . However a long time period of follow-up is required to assess the inocuity of these nanoparticles after chronic treatment in man.
These results, with bound pentamidine, show that drug carriers are of interest for the treatment of leishmaniasis. Other studies with a panel of drug carriers loaded with different drugs are now in progress.
